Neurocrine Biosciences Ownership
| NBIX Stock | USD 115.60 3.68 3.29% |
Shares in Circulation | First Issued 1996-03-31 | Previous Quarter 104.3 M | Current Value 103.7 M | Avarage Shares Outstanding 57.9 M | Quarterly Volatility 30.3 M |
Neurocrine |
Neurocrine Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The book value of Neurocrine Biosciences was now reported as 26.05. The company has Price/Earnings To Growth (PEG) ratio of 0.27. Neurocrine Biosciences last dividend was issued on the 29th of December 1995. Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. Neurocrine Bioscienc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 1150 people. To find out more about Neurocrine Biosciences contact Kevin Gorman at 858 617 7600 or learn more at https://www.neurocrine.com.Besides selling stocks to institutional investors, Neurocrine Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Neurocrine Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Neurocrine Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Neurocrine Biosciences Quarterly Liabilities And Stockholders Equity |
|
Neurocrine Biosciences Insider Trades History
Only 1.02% of Neurocrine Biosciences are currently held by insiders. Unlike Neurocrine Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Neurocrine Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Neurocrine Biosciences' insider trades
Neurocrine Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neurocrine Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurocrine Biosciences backward and forwards among themselves. Neurocrine Biosciences' institutional investor refers to the entity that pools money to purchase Neurocrine Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wellington Management Company Llp | 2024-12-31 | 1.5 M | Jpmorgan Chase & Co | 2024-12-31 | 1.4 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 983.8 K | Northern Trust Corp | 2024-12-31 | 981.9 K | Amvescap Plc. | 2024-12-31 | 949.5 K | Bnp Paribas Investment Partners Sa | 2024-12-31 | 944.7 K | Orbimed Advisors, Llc | 2024-12-31 | 938.1 K | Dsm Capital Partners Llc | 2024-12-31 | 932.6 K | Blackrock Inc | 2024-12-31 | 14.8 M | Vanguard Group Inc | 2024-12-31 | 10.1 M |
Neurocrine Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurocrine Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurocrine Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neurocrine Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neurocrine Biosciences' latest congressional trading
Congressional trading in companies like Neurocrine Biosciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Neurocrine Biosciences by those in governmental positions are based on the same information available to the general public.
| 2024-12-18 | Representative Michael McCaul | Acquired $15K to $50K | Verify | ||
| 2024-09-18 | Representative Michael McCaul | Acquired Under $15K | Verify |
Neurocrine Biosciences Outstanding Bonds
Neurocrine Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neurocrine Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neurocrine bonds can be classified according to their maturity, which is the date when Neurocrine Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US64128XAE04 Corp BondUS64128XAE04 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Neurocrine Biosciences Corporate Filings
| 6th of March 2025 Other Reports | ViewVerify | |
F4 | 14th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 10th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 6th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.